<table>
<thead>
<tr>
<th>Research Ethics Committee Reference Number</th>
<th>Name of Trial</th>
<th>Target number of patients</th>
<th>Date agreed to recruit target number of patients</th>
<th>Trial status</th>
<th>Target met within the agreed time?</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>04/MRE07/35</td>
<td>Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy</td>
<td>69</td>
<td>31/12/2020</td>
<td>Open</td>
<td>N/A</td>
<td>Date agreed to recruit to target not yet passed</td>
</tr>
<tr>
<td>07/H1102/84</td>
<td>Sunitinib treatment of renal adjuvant cancer (S-TRAC) A randomized double blind phase 3 study of adjuvant vs placebo in subjects at high risk of recurrent RCC. Study Number: A6181109</td>
<td>3</td>
<td>Closed - In Follow Up</td>
<td>N/A</td>
<td>Study delivered to target. Study has been in follow up since 2008.</td>
<td></td>
</tr>
<tr>
<td>07/Q1206/53</td>
<td>Clinical Trial Protocol CAN107A2303 - A phase III multi-center, open-label, randomized study of imatinib versus nilotinib in adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CM)</td>
<td>5</td>
<td>15/06/2008</td>
<td>Closed - In Follow Up</td>
<td>Y</td>
<td>Study delivered to time and target.</td>
</tr>
<tr>
<td>08/H1010/66</td>
<td>Protocol H3E-MC-J/MG - Phase 3 Study of Pemetrexed, cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed versus Etoposide, cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients with Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other Than Predominantly Squamous Cell Histology</td>
<td>3</td>
<td>01/01/2011</td>
<td>Closed - Follow Up Complete</td>
<td>N</td>
<td>Study reached target by May 2011 (4 months delay) and eventually recruited 12 patients in total.</td>
</tr>
<tr>
<td>08/H1102/75</td>
<td>A double-blind, randomized, multicenter, placebo controlled, parallel-group study comparing the efficacy and safety of 0.5mg FTY720 administered orally once daily versus placebo in patients with primary progressive multiple sclerosis</td>
<td>10</td>
<td>01/12/2011</td>
<td>Closed - Follow Up Complete</td>
<td>Y</td>
<td>Study delivered to time and target.</td>
</tr>
<tr>
<td>09/H0405/51</td>
<td>A Phase II Study of Dasatinib therapy in children &amp; adolescents with Ph+ leukemia with resistance or intolerance to imatinib.</td>
<td>10</td>
<td>Closed - In Follow Up</td>
<td>N/A</td>
<td>No target or date agreed with sponsor.</td>
<td></td>
</tr>
<tr>
<td>09/H0711/8</td>
<td>CompERA-XL: Comparison of endothelin receptor antagonist therapy in routine care</td>
<td>200</td>
<td>Open</td>
<td>N/A</td>
<td>No date agreed with sponsor. Study has recruited 92/200 patients.</td>
<td></td>
</tr>
<tr>
<td>10/H0408/27</td>
<td>Randomised, Multicentre, Open-label, Phase III Study of Pidotepin in Combination with Dexamethasone vs. Dexamethasone Alone in Patients with Relapsed/Refractory Multiple Myeloma</td>
<td>6</td>
<td>Closed - In Follow Up</td>
<td>N/A</td>
<td>No date agreed with sponsor.</td>
<td></td>
</tr>
<tr>
<td>10/H0605/58</td>
<td>Sub Study to study WN25203 using positron emission tomography (PET) with an amyloid tracer to assess changes in amyloid load over time in subjects with Prodromal Alzheimer’s Disease</td>
<td>1</td>
<td>30/09/2012</td>
<td>Closed - In Follow Up</td>
<td>Y</td>
<td>Study delivered to time and target.</td>
</tr>
<tr>
<td>10/H0605/59</td>
<td>Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RD9099832 on Cognition and Function in Prodromal Alzheimer’s Disease (WN25203)</td>
<td>6</td>
<td>01/09/2013</td>
<td>Closed - In Follow Up</td>
<td>Y</td>
<td>Study delivered to time and target.</td>
</tr>
<tr>
<td>10/H0713/35</td>
<td>An International, multi-center, randomized, controlled trial evaluating the effect of xenon on post-operative delirium in elderly patients undergoing hip fracture surgery</td>
<td>6</td>
<td>31/10/2014</td>
<td>Closed - In Follow Up</td>
<td>Y</td>
<td>Study delivered to time and target.</td>
</tr>
<tr>
<td>10/H0715/57</td>
<td>A Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy</td>
<td>5</td>
<td>01/11/2011</td>
<td>Closed - In Follow Up</td>
<td>Y</td>
<td>Study delivered to time and target.</td>
</tr>
<tr>
<td>10/H0717/68</td>
<td>A Phase III, Double-blind, Randomized, Placebo-Controlled, Multicenter, Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V2212/Inactivated Varicella-Zoster Virus (VZV) Vaccine in Recipients of Autologous Hematopoietic</td>
<td>3</td>
<td>25/04/2013</td>
<td>Closed - In Follow Up</td>
<td>Y</td>
<td>Study delivered to time and target.</td>
</tr>
<tr>
<td>10/H0801/67</td>
<td>Focal MR-Guided Focused Ultrasound Treatment of Localized Low-Risk Prostate Cancer: Feasibility Study</td>
<td>15</td>
<td>17/07/2016</td>
<td>Open</td>
<td>N/A</td>
<td>Date agreed to recruit to target not yet passed.</td>
</tr>
<tr>
<td>10/H0904/49</td>
<td>A single arm, open-label, multicenter study evaluating the long-term safety, tolerability and efficacy of 0.5mg fingolimod (FTY720) administered orally once daily in patients with multiple sclerosis</td>
<td>10</td>
<td>01/12/2011</td>
<td>Closed - In Follow Up</td>
<td>Y</td>
<td>Study delivered to time and target.</td>
</tr>
<tr>
<td>11/EE/0256</td>
<td>Multi-centre, open label, prospective, consecutive series registry database of BioPoly RS Partial Resurfacing Knee implant</td>
<td>10</td>
<td>31/12/2015</td>
<td>Open</td>
<td>N/A</td>
<td>Date agreed to recruit to target not yet passed.</td>
</tr>
<tr>
<td>Study ID</td>
<td>Study Title</td>
<td>Phase</td>
<td>Sponsor</td>
<td>Dates</td>
<td>Status</td>
<td>Recruitment</td>
</tr>
<tr>
<td>-----------</td>
<td>-----------------------------------------------------------------------------</td>
<td>-------</td>
<td>---------</td>
<td>---------------------</td>
<td>-------------------------</td>
<td>-------------</td>
</tr>
<tr>
<td>11/EM/0074</td>
<td>A 2-Year, multicenter, double-masked, randomised, parallel study of the safety of LUMIGAN 0.1 mg/mL compared with LUMIGAN 0.3 mg/mL in patients with glaucoma or ocular hypertension</td>
<td>15</td>
<td>Y</td>
<td>11/EM/0074</td>
<td>Closed - In Follow Up</td>
<td>Y</td>
</tr>
<tr>
<td>11/LO/0449</td>
<td>A multicenter, global, randomized, double-blind study of astinib versus placebo in patients with advanced hepatocellular carcinoma following failure of one prior antiangiogenic therapy</td>
<td>2</td>
<td>Y</td>
<td>11/LO/0449</td>
<td>Closed - In Follow Up</td>
<td>Y</td>
</tr>
<tr>
<td>11/LO/0537</td>
<td>A Multicenter, randomized, double-blind, placebo-controlled Study of the Efficacy of Natalizumab or Reducing Disability Progression in Subjects with Secondary Progressive Multiple Sclerosis</td>
<td>20</td>
<td>Y</td>
<td>11/LO/0537</td>
<td>Closed - In Follow Up</td>
<td>Y</td>
</tr>
<tr>
<td>11/LO/0551</td>
<td>A phase I Open-Label Dose Escalation Study of the Focal Adhesion Kinase Inhibitor, GSK2256098, in Subjects with Solid Tumors</td>
<td>10</td>
<td>N/A</td>
<td>11/LO/0551</td>
<td>Closed - Follow Up Complete</td>
<td>N/A</td>
</tr>
<tr>
<td>11/LO/1040</td>
<td>A long-term monitoring study to evaluate the persistence of direct acting antiviral (DAV) treatment-resistant mutations or the durability of sustained virological response (SVR) in patients treated with DAA-containing regimens for chronic hepatitis C infection (CHC) NV22688</td>
<td>2</td>
<td>N/A</td>
<td>11/LO/1040</td>
<td>Closed - Follow Up Complete</td>
<td>N/A</td>
</tr>
<tr>
<td>11/LO/1369</td>
<td>A Randomized, Double-Blind, Multi-Center Phase 3 Study of ADI-PEG 20 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed Prior Systemic Therapy</td>
<td>1</td>
<td>Y</td>
<td>11/LO/1369</td>
<td>Closed - In Follow Up</td>
<td>Y</td>
</tr>
<tr>
<td>11/LO/1904</td>
<td>A randomized double-blind multiple-dose placebo-controlled trial to establish the efficacy of QBX258 (combination of VAK694 and QAX76) in asthma that is inadequately controlled with inhaled corticosteroids and long acting beta agonists</td>
<td>6</td>
<td>Y</td>
<td>11/LO/1904</td>
<td>Closed - Follow Up Complete</td>
<td>Y</td>
</tr>
<tr>
<td>11/NW/0298</td>
<td>A multicenter, phase III, open-label, randomized study in previously untreated patients with advanced indolent non Hodgkins Lymphoma comparing GA101 (RO5072759) plus chemotherapy with rituximab plus chemotherapy followed by GA101 or rituximab mainten</td>
<td>2</td>
<td>Y</td>
<td>11/NW/0298</td>
<td>Closed - Follow Up Complete</td>
<td>Y</td>
</tr>
<tr>
<td>11/SC/0454</td>
<td>A phase IIb parallel group, open label study of pegylated interferon alfa-2a monotherapy (PEG-IFN, RO 25-8310) compared to untreated control in children with HBeAg positive chronic hepatitis B</td>
<td>2</td>
<td>Y</td>
<td>11/SC/0454</td>
<td>Closed - In Follow Up</td>
<td>Y</td>
</tr>
<tr>
<td>11/WS/0039</td>
<td>A Phase II trial of AZD4547 in combination with Cisplatin and Capcetabine (CX)</td>
<td>1</td>
<td>Y</td>
<td>11/WS/0039</td>
<td>Closed - Follow Up Complete</td>
<td>Y</td>
</tr>
<tr>
<td>12/EE/0176</td>
<td>Randomised, phase IV, placebo-controlled, comparative study to evaluate the efficacy and safety of tapering methotrexate (MTX) dosage versus maintaining the dosage in patients with severe active rheumatoid arthritis (RA) who have demonstrated an inad</td>
<td>5</td>
<td>N</td>
<td>12/EE/0176</td>
<td>Closed - Follow Up Complete</td>
<td>N</td>
</tr>
<tr>
<td>12/LO/0098</td>
<td>A randomized, doubleblind, placebo controlled, multiple dose study to evaluate the safety, tolerability, and efficacy of intravenous administration of secukinumab (AIN457) in patients with asthma not adequately controlled with inhaled corticosteroids</td>
<td>6</td>
<td>Y</td>
<td>12/LO/0098</td>
<td>Closed - Follow Up Complete</td>
<td>Y</td>
</tr>
<tr>
<td>12/LO/0858</td>
<td>An OpenLabel Study to Evaluate the Safety, Antiviral Activity and Pharmacokinetics of Direct Acting Antiviral Agent (DAAV) Treatment in Combination with Peginterferon alfa-2a and Ribavirin (pegIFN/RBV) in Chronic Hepatitis C Virus (HCV) Infected Subjects</td>
<td>N/A</td>
<td>N/A</td>
<td>12/LO/0858</td>
<td>Closed - Follow Up Complete</td>
<td>N/A</td>
</tr>
<tr>
<td>12/LO/1173</td>
<td>An Open Label Phase I/II Study of GSK2210183 in Combination with Carboplatin and Paclitaxel in Subjects with PlatinumResistant Ovarian Cancer</td>
<td>10</td>
<td>Y</td>
<td>12/LO/1173</td>
<td>Closed - Follow Up Complete</td>
<td>Y</td>
</tr>
<tr>
<td>12/LO/1320</td>
<td>Aneurysm Treatment using the HeLiFX Aortic Securement System Global Registry</td>
<td>5</td>
<td>N</td>
<td>12/LO/1320</td>
<td>26/11/2013</td>
<td>Open</td>
</tr>
<tr>
<td>12/LO/1343</td>
<td>A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating CNTO 3157 in Healthy Normal and Asthmatic Subjects Inoculated with Human Rhinovirus Type 16</td>
<td>2</td>
<td>Y</td>
<td>12/LO/1343</td>
<td>Closed - Follow Up Complete</td>
<td>Y</td>
</tr>
<tr>
<td>Study ID</td>
<td>Title Description</td>
<td>N</td>
<td>Start Date</td>
<td>End Date</td>
<td>Status</td>
<td>Protocol Delivered to Time and Target</td>
</tr>
<tr>
<td>----------</td>
<td>-------------------</td>
<td>---</td>
<td>------------</td>
<td>----------</td>
<td>--------</td>
<td>-------------------------------------</td>
</tr>
<tr>
<td>12/LO/1597</td>
<td>A randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 co-administered with Ribavirin (RBV) in treatment-naive adults with genotype 1 chronic hepatitis C virus (HCV) infection and cirrhosis</td>
<td>5</td>
<td>01/04/2013</td>
<td>Closed - Follow Up Complete</td>
<td>Y</td>
<td>Study delivered to time and target.</td>
</tr>
<tr>
<td>12/LO/1598</td>
<td>A randomized, open label study to evaluate the safety and efficacy of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 (coadministered with Ribavirin (RBV)) in adults with genotype 1 chronic hepatitis C virus (HCV) infection and cirrhosis</td>
<td>4</td>
<td>31/03/2013</td>
<td>Closed - Follow Up Complete</td>
<td>Y</td>
<td>Study delivered to time and target.</td>
</tr>
<tr>
<td>12/LO/1698</td>
<td>Valacyclovir in Delaying Antiretroviral Treatment Entry (VALIDATE) Short</td>
<td>10</td>
<td>31/12/2014</td>
<td>Closed - In Follow Up</td>
<td>N</td>
<td>Recruitment has been difficult worldwide - only managed to recruit 192/480 globally. Several other sites have also not reached their target. Study team has spoken to many possible participants but they have declined to take part.</td>
</tr>
<tr>
<td>12/LO/1762</td>
<td>Left ventricular MultiSpot Pacing for CRT (i-Spot)</td>
<td>8</td>
<td>24/12/2015</td>
<td>Closed - Follow Up Complete</td>
<td>N</td>
<td></td>
</tr>
<tr>
<td>12/LO/1823</td>
<td>A Randomized, Double-blind Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV 1 Infection</td>
<td>10</td>
<td>19/12/2013</td>
<td>Closed - In Follow Up</td>
<td>N</td>
<td>2 patients recruited.</td>
</tr>
<tr>
<td>12/LO/1861</td>
<td>A Randomised, Open-label, Active-controlled, Multi-centre Study to Evaluate the Safety of Rivaroxaban and Vitamin K Antagonists in Subjects Undergoing Catheter Ablation for Atrial Fibrillation</td>
<td>8</td>
<td>30/06/2014</td>
<td>Closed - Follow Up Complete</td>
<td>Y</td>
<td>Study delivered to time and target.</td>
</tr>
<tr>
<td>12/LO/1889</td>
<td>Openlabel,single arm extension study to the doubleblind,randomized, multicenter, placebo controlled,parallel group study comparing the efficacy and safety of 0.5 mg FTY720 administered orally once daily versus placebo in patients with primary progress</td>
<td>6</td>
<td>31/08/2014</td>
<td>Closed - Follow Up Complete</td>
<td>Y</td>
<td>Study delivered to time and target.</td>
</tr>
<tr>
<td>12/LO/1966</td>
<td>A Phase 3, Randomized, Placebo-controlled, Parallel-group, Multicenter, Doubleblind Study to Evaluate the Efficacy and Safety of Telotristat Etiprate (LX1606) in Patients with Carcinoid Syndrome Refractory to Somatostatin Analog [SSA] Therapy</td>
<td>1</td>
<td>31/12/2014</td>
<td>Closed - In Follow Up</td>
<td>Y</td>
<td>Study delivered to time and target.</td>
</tr>
<tr>
<td>12/LO/1981</td>
<td>A Randomized, Multicenter, Open-Label Phase III Study To Evaluate The Efficacy And Safety Of Trastuzumab Emtansine Versus Trastuzumab As Adjuvant Therapy For Patients With Her2-Positive Primary Breast Cancer Who Have Residual Tumor Present Pathologic</td>
<td>3</td>
<td>01/03/2016</td>
<td>Open</td>
<td>Y</td>
<td>Study delivered to time and target.</td>
</tr>
<tr>
<td>12/NW/0137</td>
<td>A randomized, double-blind, multicenter, Phase III study of everolimus [RAD001] plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of GI or lung origin</td>
<td>5</td>
<td>03/11/2014</td>
<td>Closed - In Follow Up</td>
<td>Y</td>
<td>Study delivered to time and target.</td>
</tr>
<tr>
<td>12/NW/0251</td>
<td>A multicentre, stratified, open, comparator-controlled, parallelgroup phase III study comparing treatment with 177Lu-DOTA-Tyr3-Octreotate to Octreotide LAR in patients with inoperable, progressive, somatostatin receptor positive, midgut NET</td>
<td>3</td>
<td>01/06/2015</td>
<td>Closed - Follow Up Complete</td>
<td>Y</td>
<td>Study delivered to time and target.</td>
</tr>
<tr>
<td>12/NW/0711</td>
<td>Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Month Trial of Leucovorin-methylthioninium bis(hydromethanesulfonate) in Subjects with Mild to Moderate Alzheimer’s Disease (1rx-237-015)</td>
<td>10</td>
<td>01/01/2014</td>
<td>Closed - Follow Up Complete</td>
<td>Y</td>
<td>Study delivered to time and target.</td>
</tr>
<tr>
<td>12/SC/0538</td>
<td>A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of Leucovorin-methylthioninium bis(hydromethanesulfonate) in Subjects with Behavioral Variant Frontotemporal Dementia (bvFTD)</td>
<td>6</td>
<td>01/01/2014</td>
<td>Closed - In Follow Up</td>
<td>N</td>
<td>7 patients recruited to date.</td>
</tr>
<tr>
<td>12/SS/0007</td>
<td>A randomised Phase 2 Placebo-Controlled Study of LY2495655 in Patients with Advanced or Metastatic Pancreatic Cancer Receiving Chemotherapy</td>
<td>4</td>
<td>30/01/2014</td>
<td>Closed - In Follow Up</td>
<td>N</td>
<td>Rare disease study. There were 2 patients recruited.</td>
</tr>
<tr>
<td>Code</td>
<td>Title</td>
<td>Design</td>
<td>Phase</td>
<td>Start Date</td>
<td>Status</td>
<td>Enrollment Details</td>
</tr>
<tr>
<td>----------</td>
<td>-----------------------------------------------------------------------</td>
<td>-----------------------------</td>
<td>-------</td>
<td>------------</td>
<td>-------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>12/SW/0378</td>
<td>Effect of BivalRudin on Aortic Valve Intervention Outcomes 2/3 (BRAVO 2/3)</td>
<td>A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular events When AMG 145 is Used in Combination With StatinTherapy in Patients with Clinically Evident C</td>
<td>6</td>
<td>02/02/2015</td>
<td>Open</td>
<td>Bereavement in study team and after discussion with the study sponsors, we therefore agreed to postpone start of recruitment. First patient was consented in September 2014.</td>
</tr>
<tr>
<td>12/WM/0341</td>
<td>A randomised trial in new hearing aid users to measure the benefit of using 4 pre-set configurations of hearing aids with self learning characteristics</td>
<td>Multi-Center, Open-Label, Randomized Study of Anti-CCR4 Monoclonal Antibody/KW-0761 or Investigators Choice in Subjects with Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)</td>
<td>53</td>
<td>30/11/2014</td>
<td>Closed - Follow Up Complete</td>
<td>41 patients recruited to date.</td>
</tr>
<tr>
<td>12/WM/0373</td>
<td>A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia</td>
<td>An Exploratory Study of the Safety and Efficacy of BOTOX for the Treatment of Premature Ejaculation</td>
<td>4</td>
<td>29/11/2016</td>
<td>Open</td>
<td>Study delivered to time and target.</td>
</tr>
<tr>
<td>12/WS/0184</td>
<td>A randomized trial in new hearing aid users to measure the benefit of using 4 pre-set configurations of hearing aids with self learning characteristics</td>
<td>A randomised trial in new hearing aid users to measure the benefit of using 4 pre-set configurations of hearing aids with self learning characteristics</td>
<td>3</td>
<td>30/06/2014</td>
<td>Open</td>
<td>Study delivered to time and target.</td>
</tr>
<tr>
<td>11/YH/0318</td>
<td>A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia</td>
<td>A Long-Term Follow-up Study to Evaluate the Durability of Virologic Response and/or Viral Resistance Patterns of Subjects with Chronic Hepatitis C Who Have Been Previously Treated with MK-5172 in a Prior Clinical Trial</td>
<td>5</td>
<td>02/07/2014</td>
<td>Closed - Follow Up Complete</td>
<td>Study delivered to time and target.</td>
</tr>
<tr>
<td>12/YH/0504</td>
<td>A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular events When AMG 145 is Used in Combination With StatinTherapy in Patients with Clinically Evident C</td>
<td>A Long-Term Follow-up Study to Evaluate the Durability of Virologic Response and/or Viral Resistance Patterns of Subjects with Chronic Hepatitis C Who Have Been Previously Treated with MK-5172 in a Prior Clinical Trial</td>
<td>10</td>
<td>01/08/2015</td>
<td>Open</td>
<td>Date agreed to recruit to target not yet passed.</td>
</tr>
<tr>
<td>13/EE/0199</td>
<td>A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular events When AMG 145 is Used in Combination With StatinTherapy in Patients with Clinically Evident C</td>
<td>A Phase II Clinical Trial to Study the Efficacy and Safety of a combination regimen of MK-5172 and MK-8742 withRibavirin (RBV) in Subjects with Chronic Hepatitis C Genotype 2 Infection</td>
<td>1</td>
<td>30/09/2018</td>
<td>Open</td>
<td>Study delivered to time and target.</td>
</tr>
<tr>
<td>13/EE/0214</td>
<td>A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular events When AMG 145 is Used in Combination With StatinTherapy in Patients with Clinically Evident C</td>
<td>A Doubleblind, randomized, placebocontrolled, study to demonstrate the efficacy and safety of 250 mg or 1 g A3384 administered orally twice daily for two weeks to patients with Bile Acid Malabsorption (BAM)/Bile Acid Diarrhea (BAD)</td>
<td>12</td>
<td>31/05/2015</td>
<td>Closed - In Follow Up</td>
<td>Study delivered to time and target.</td>
</tr>
<tr>
<td>13/EE/0429</td>
<td>A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular events When AMG 145 is Used in Combination With StatinTherapy in Patients with Clinically Evident C</td>
<td>A doubleblind, randomized, placebocontrolled, study to demonstrate the efficacy and safety of 250 mg or 1 g A3384 administered orally twice daily for two weeks to patients with Bile Acid Malabsorption (BAM)/Bile Acid Diarrhea (BAD)</td>
<td>6</td>
<td>06/07/2015</td>
<td>Open</td>
<td>No date agreed with sponsor.</td>
</tr>
<tr>
<td>13/EE/0444</td>
<td>A Phase II/III open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in subjects with relapsed, refractory hematologic malignancies.</td>
<td>Maximizing CRT Delivery by using Multipolar Coronary Sinus Lead Acuity x4</td>
<td>20</td>
<td>31/12/2014</td>
<td>Open</td>
<td>5 patients recruited into the study. Team continues to try to identify new patients.</td>
</tr>
<tr>
<td>13/EM/0348</td>
<td>A Phase II/III open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in subjects with relapsed, refractory hematologic malignancies.</td>
<td>Safety and efficacy assessment of Monoprost? (unpreserved latanoprost) in comparison with Lumigan? 0.01 % and Lumigan? 0.03% UD, in patients with primary open angle glaucoma or ocular hypertension, stabilized by Lumigan? 0.01 % withocular surfac</td>
<td>6</td>
<td>31/08/2015</td>
<td>Closed - In Follow Up</td>
<td>Study delivered to time and target.</td>
</tr>
<tr>
<td>13/EM/0374</td>
<td>A Phase II/III open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in subjects with relapsed, refractory hematologic malignancies.</td>
<td>Safety and efficacy assessment of Monoprost? (unpreserved latanoprost) in comparison with Lumigan? 0.01 % and Lumigan? 0.03% UD, in patients with primary open angle glaucoma or ocular hypertension, stabilized by Lumigan? 0.01 % withocular surfac</td>
<td>20</td>
<td>31/12/2014</td>
<td>Open</td>
<td>No target or date agreed with sponsor. There have been 12 patients recruited. Although team was consenting and screening early on, there was a high dropout rate delaying the date of first patient recruited.</td>
</tr>
</tbody>
</table>
A RANDOMIZED, MULTICENTER, OPEN-LABEL TRIAL COMPARING CHEMOTHERAPY PLUS TRASTUZUMAB PLUS PERTUZUMAB VERSUS CHEMOTHERAPY PLUS TRASTUZUMAB EMΤANSINE PLUS PERTUZUMAB AS ADJUVANT THERAPY IN PATIENTS WITH OPERABLE HER2 POSITIVE PRIMARY BREAST CANCER

Study closed to recruitment early (nationally) by the Sponsor (closed 22/05/2015) which is why we did not recruit to time and target. This was due to newly available data from the phase III MARIANNE study.

A Phase 4 Cross-Sectional Study of Bone Mineral Density in HIV-1 Infected Subjects

Several months delay in Sponsor conducting site initiation - impacted on site's ability to recruit in that period. Total of 3 patients recruited.

A Randomized, Double blind, placebo-controlled, multicenter phase III study of regorafenib in patients with hepatocellular carcinoma (HCC) after sorafenib

Study had very tight UK set-up timelines; it was already almost fully recruited in the US when UK sites were opened. UK sites only had 4 days to recruit (6-May to 10-May-13). Follow up ended on 27/08/2014.

A PHASE 2, RANDOMIZED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND ANTI-CYTOMEGALOVIRUS (CMV) ACTIVITY OF MARIBAVIR VERSUS VALGANCICLOVIR FOR TREATMENT OF CMV INFECTIONS IN TRANSPLANT RECIPIENTS WHO DO NOT HAVE CMV ORGAN DISEASE

Sponsor required extensive protocol-specific training in various electronic systems, which delayed set-up of the study here because of the large number of people involved that would need to undertake this training. Recruitment was closed by Sponsor before our site had a chance to enrol a patient.

A Randomized Controlled Phase 3 Study of Oral Pacritinib versus Best Available Therapy in Patients with Primary Myelofibrosis, Post-Polycthemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

Study delivered to time and target.

A Randomized Controlled, Open-Label, Phase 2, Trial of SGi-110 and Carboplatin in Subjects with Platinum-Resistant Recurrent Ovarian Cancer

Study delivered to time and target.

A Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects With Multiple Sclerosis Who Have Completed Study 205MS301

No date agreed with sponsor.

A Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer

Study delivered to time and target.
<table>
<thead>
<tr>
<th>Study Number</th>
<th>Description</th>
<th>Study Status</th>
<th>Target Achieved</th>
<th>Conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>13/LO/1302</td>
<td>A Phase IIIb randomised, openlabel study of the safety and efficacy of dolutegravir/abacavir/lamivudine once daily compared to atazanavir and ritonavir plus tenofovir/emtricitabine once daily in HIV1 infected antiretroviral therapy naive women.</td>
<td>Closed - In Follow Up</td>
<td>Y</td>
<td>Study delivered to time and target.</td>
</tr>
<tr>
<td>13/LO/1323</td>
<td>The efficacy and safety of Ferriprox for the treatment of transfusional iron overload in patients with sickle cell disease or other anaemias</td>
<td>Open</td>
<td>N</td>
<td>Study team has confirmed that of the 5 patients seen across the Trust during the recruitment period, 2 failed screening. This resulted in the target number (5) being missed. In addition, due to the significant SIV and IMP delivery delay, the time to recruit had been reduced.</td>
</tr>
<tr>
<td>13/LO/1332</td>
<td>A TwoPart Phase 1/2a, OpenLabel, Dose Escalation Study to Evaluate the Tolerability and Preliminary Antitumour Activity of OPB111001 in Patients with Advanced Cancers that are Poorly Responsive to Standard Anticancer Treatment</td>
<td>Suspended</td>
<td>N/A</td>
<td>No date agreed with sponsor.</td>
</tr>
<tr>
<td>13/LO/1352</td>
<td>A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF MPDL3280A (ANTI-PD-L1 ANTIBODY) COMPARED WITH DOCEТАКЕЛЬ IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AFTER PLATINUM FAILURE</td>
<td>Closed - In Follow Up</td>
<td>Y</td>
<td>Study delivered to time and target.</td>
</tr>
<tr>
<td>13/LO/1557</td>
<td>A Phase IV, Multicentre, Open label, Single Group Exploratory Study to Assess the Clinical Value of Enumeration of Circulating Tumour Cells (CTCs) to Predict Clinical Symptomatic Response and Progression Free Survival in Patients receiving Deep Subcu</td>
<td>Open</td>
<td>N/A</td>
<td>Date agreed to recruit to target not yet passed.</td>
</tr>
<tr>
<td>13/LO/1682</td>
<td>A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients with Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian,</td>
<td>Open</td>
<td>N/A</td>
<td>Date agreed to recruit to target not yet passed.</td>
</tr>
<tr>
<td>13/LO/1758</td>
<td>A Phase III, Randomized, PlaceboControlled, ParallelGroup, DoubleBlind Clinical Trial to Study the Efficacy and Safety of MK8931 (SCH 900931) in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal AD).</td>
<td>Open</td>
<td>N/A</td>
<td>No target or date agreed with sponsor. 6 patients recruited to date</td>
</tr>
<tr>
<td>13/LO/1814</td>
<td>A phase III, randomized, controlled, single-blind, multicentre, parallel arm trial to assess the efficacy and safety of Pergoveris? (folitropin alfa and lutropin alfa) and GONAL-f? (folitropin alfa)</td>
<td>Closed - In Follow Up</td>
<td>N/A</td>
<td>No target/date agreed with sponsor.</td>
</tr>
<tr>
<td>13/NE/0125</td>
<td>PRESTO Neo.1.C/F</td>
<td>Withdrawn</td>
<td>N</td>
<td>Screened large numbers of patients comparable with other sites but have been unable to recruit. The intervention timing is challenging for new mothers who are breast feeding. The sponsor has acknowledged these challenges across all open sites. Study was eventually withdrawn.</td>
</tr>
<tr>
<td>13/NE/0126</td>
<td>An exploratory, randomised, doubleblind, controlled study to assess the effect of an Amino Acid Based Formula with a symbiotic blend on gut microbiota and stool in infants with suspected gastrointestinal Non IgE mediated cow's milk allergy - ASSIGN NEO.1.C/F</td>
<td>Closed - Follow Up Complete</td>
<td>N</td>
<td>Inclusion criteria was an obstacle as the cut off is 13 months of age. The age of referred children is older and they are therefore excluded.</td>
</tr>
<tr>
<td>Study ID</td>
<td>Title</td>
<td>Study Type</td>
<td>Status</td>
<td>Date</td>
</tr>
<tr>
<td>-----------</td>
<td>-----------------------------------------------------------------------</td>
<td>---------------------------------</td>
<td>-----------------</td>
<td>------------------------------------------------</td>
</tr>
<tr>
<td>13/NE/0177</td>
<td>A phase II, randomised, double-blind, placebo-controlled study to evaluate LUM001, an apical sodium-dependent bile acid transporter inhibitor (ASBTi), in combination with ursodeoxycholic acid (UDCA) in patients with primary biliary cirrhosis</td>
<td>Closed - Follow Up Complete</td>
<td>N</td>
<td>Rare disease study.</td>
</tr>
<tr>
<td>13/NW/0002</td>
<td>A multicenter Openlabel Extension (OLE) Study to Assess the Long term Safety and Efficacy of AMG 145</td>
<td>Open</td>
<td>N/A</td>
<td>No target or date agreed with sponsor.</td>
</tr>
<tr>
<td>13/NW/0634</td>
<td>A multicenter, randomized, double-blind Trial to Evaluate Metformin Extended Release Monotherapy Compared to Metformin Immediate Release Monotherapy in Adult Subjects with Type 2 Diabetes who have Inadequate GI</td>
<td>Open</td>
<td>N/A</td>
<td>Date agreed to recruit to target not yet passed.</td>
</tr>
<tr>
<td>Study ID</td>
<td>Title</td>
<td>Phase</td>
<td>Intervention</td>
<td>Start Date</td>
</tr>
<tr>
<td>----------</td>
<td>-------</td>
<td>-------</td>
<td>--------------</td>
<td>------------</td>
</tr>
<tr>
<td>13/SC/0311</td>
<td>A randomized, controlled, doubleblind Phase III trial to compare the efficacy, safety and pharmacokinetics of GP2013 plus cyclophosphamide, vincristine, prednisone vs. MabThera plus cyclophosphamide, vincristine, prednisone, followed by GP2013</td>
<td>3</td>
<td>31/12/2014</td>
<td>Closed - In Follow Up</td>
</tr>
<tr>
<td>13/SC/0348</td>
<td>A randomized, OpenLabel, Phase 2 Study Evaluating LY2875358 Plus Erlotinib and LY2875358 Monotherapy in MET Diagnostic Positive NSCLC Patients with Acquired Resistance to Erlotinib</td>
<td>3</td>
<td>01/10/2014</td>
<td>Closed - Follow Up Complete</td>
</tr>
<tr>
<td>13/SC/0360</td>
<td>A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa 2a and Ribavirin, Each Administered with Telaprevir in Subjects with Genotype-1 Chronic Hepatitis C who are Treatment-Naive or Relapsed on Trea</td>
<td>4</td>
<td>21/10/2013</td>
<td>Closed - Follow Up Complete</td>
</tr>
<tr>
<td>13/SC/0383</td>
<td>A Two Part, Randomized Clinical Trial to Study Biomarkers of MK8237 (SCH 900237) Treatment in Subjects with House Dust Mite Induced Allergic Rhinitis or Rhinocconjunctivitis</td>
<td>20</td>
<td>31/03/2015</td>
<td>Closed - In Follow Up</td>
</tr>
<tr>
<td>13/SC/0559</td>
<td>A Phase 3, Randomized, Placebo-controlled, Multicenter, Double-blind Study to Evaluate the Safety and Efficacy of Telotristat Etiprate (LX1606) in Patients with Carcinoid Syndrome</td>
<td>2</td>
<td>31/03/2015</td>
<td>Closed - In Follow Up</td>
</tr>
<tr>
<td>13/SC/0589</td>
<td>Optimisation of Onpulse technology for patients with post surgical or vascular oedema</td>
<td>10</td>
<td>30/07/2014</td>
<td>Closed - Follow Up Complete</td>
</tr>
<tr>
<td>13/SW/0124</td>
<td>A PERFORMANCE EVALUATION STUDY OF UROSENS? MCM5-ELISA FOR THE DETECTION OF PROSTATE CANCER IN PATIENTS WITH KNOWN DISEASE AND IN THOSE PRESENTING WITH RAISED SERUM PROSTATE-SPECIFIC ANTIGEN AND/OR ABNORMAL PROSTATE GLAND MORPHOLOGY</td>
<td>19</td>
<td>28/02/2014</td>
<td>Closed - In Follow Up</td>
</tr>
<tr>
<td>13/WA/0064</td>
<td>A performance evaluation study of UROSENS Mmcs ELISA test in the diagnosis of bladder cancer in patients presenting with haematuria and lower urinary tract symptoms with suspicion of malignancy</td>
<td>250</td>
<td>15/01/2014</td>
<td>Closed - In Follow Up</td>
</tr>
<tr>
<td>13/WA/0328</td>
<td>Randomized controlled study comparing AEZS-108 with doxorubicin as second line therapy for locally advanced, recurrent or metastatic endometrial cancer</td>
<td>2</td>
<td>31/07/2015</td>
<td>Open</td>
</tr>
<tr>
<td>13/WS/0172</td>
<td>A Phase 2, Open-Label Study of Rucaparib in Patients with Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer</td>
<td>8</td>
<td>13/12/2015</td>
<td>Suspended</td>
</tr>
<tr>
<td>13/WS/0282</td>
<td>Prospective, single-arm, global multi-center study to evaluate treatment of obstructive superficial femoral artery and/or popliteal lesions with a novel paclitaxel coated percutaneous angioplasty balloon</td>
<td>10</td>
<td>01/01/2016</td>
<td>Closed - In Follow Up</td>
</tr>
<tr>
<td>13/YH/0275</td>
<td>Revitive for the treatment of venous insufficiency</td>
<td>20</td>
<td>01/07/2014</td>
<td>Closed - Follow Up Complete</td>
</tr>
<tr>
<td>13/YH/0317</td>
<td>Current Steering to Optimize Deep Brain Stimulation</td>
<td>4</td>
<td>30/11/2014</td>
<td>Closed - Follow Up Complete</td>
</tr>
<tr>
<td>14/EM/0130</td>
<td>A Phase 3, Open-Label, Randomized Study of Quizartinib (AC220) Monotherapy vs. Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory to, or Relapsed after, First-Line Treatment</td>
<td>2</td>
<td>30/06/2016</td>
<td>Open</td>
</tr>
<tr>
<td>14/EM/0186</td>
<td>A Randomized Controlled Phase 3 Study of Oral Pacritinib versus Best Available Therapy in Patients with Thrombocytopoenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis</td>
<td>2</td>
<td>14/08/2018</td>
<td>Open</td>
</tr>
<tr>
<td>Study ID</td>
<td>Title</td>
<td>Status</td>
<td>Date agreed to recruit to target</td>
<td>Date agreed to target not yet passed</td>
</tr>
<tr>
<td>---------------</td>
<td>-------------------------------------------------------------------------------------------</td>
<td>-----------------</td>
<td>----------------------------------</td>
<td>--------------------------------------</td>
</tr>
<tr>
<td>14/EM/1039</td>
<td>A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura</td>
<td>1</td>
<td>14/11/2015</td>
<td>N/A</td>
</tr>
<tr>
<td>14/EM/1059</td>
<td>A Phase 3, Open Label Extension Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura</td>
<td>1</td>
<td>14/11/2015</td>
<td>N/A</td>
</tr>
<tr>
<td>14/LO/0102</td>
<td>A First Time in Human, Double Blind, Randomized, Placebo Controlled Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Intravenous Doses of SNF472 in Healthy Male Volunteers</td>
<td>8</td>
<td>Open</td>
<td>N/A</td>
</tr>
<tr>
<td>14/LO/0362</td>
<td>Prospective, randomized, placebo-controlled, double-blind, multicenter, parallel-group, 24-week study to assess the efficacy, safety and tolerability of macitentan in subjects with inoperable chronic thromboembolic pulmonary hypertension</td>
<td>3</td>
<td>28/08/2015</td>
<td>N/A</td>
</tr>
<tr>
<td>14/LO/0521</td>
<td>A prospective, randomized, open label, two arm Phase III study to evaluate treatment free remission (TFR) rate in patients with Philadelphia positive CML after two different durations of consolidation treatment with nilotinib 300mg BID</td>
<td>1</td>
<td>01/12/2019</td>
<td>Y</td>
</tr>
<tr>
<td>14/LO/0665</td>
<td>A Phase III Open Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK5172/ MK8742 in Treatment Na/ve Subjects with Chronic HCV GT1, GT4, GT5, and GT6 Infection who are on Opiate Substitution Therapy.</td>
<td>4</td>
<td>Closed - Follow Up Complete</td>
<td>N/A</td>
</tr>
<tr>
<td>14/LO/0673</td>
<td>A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS 1101 (CAL-101) in Combination with Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia</td>
<td>7</td>
<td>31/03/2018</td>
<td>N/A</td>
</tr>
<tr>
<td>14/LO/0717</td>
<td>A Multicenter Phase 3 Randomized Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukaemia.</td>
<td>2</td>
<td>12/05/2020</td>
<td>Y</td>
</tr>
<tr>
<td>14/LO/0865</td>
<td>A Phase 2, Multi-Center, Randomized, Double-Blind, Ascending Dose, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of IgA Nephropathy.</td>
<td>5</td>
<td>Open</td>
<td>N/A</td>
</tr>
<tr>
<td>14/LO/0882</td>
<td>A PHASE III, OPEN-LABEL, MULTICENTER,RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF MPDL3280A (ANTI-PD-L1 ANTIBOD) COMPARED WITH DOCEATXEL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AFTER FAILURE WITH PLATINUM-CONTAINING CHEMOTHERAPY</td>
<td>4</td>
<td>01/06/2015</td>
<td>Y</td>
</tr>
<tr>
<td>14/LO/1053</td>
<td>A Phase 3 Randomised double blind Active study Evaluating Memelotinib vs Ruxolitinib in subjects with primary Myelofibrosis (PMF) or Post-poly cythemia Vera or Post-essential Thrombocythemia Myelofibrosis ( Post-PV/ET MF)</td>
<td>2</td>
<td>01/12/2017</td>
<td>N/A</td>
</tr>
<tr>
<td>14/LO/1381</td>
<td>A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Reformulated Raltegravir 1200 mg Once Daily versus Raltegravir 400 mg Twice Daily, Each in Combination with TRUVADA</td>
<td>5</td>
<td>30/04/2015</td>
<td>N</td>
</tr>
<tr>
<td>14/LO/1728</td>
<td>A Phase Ib Open Label Study of the Safety and Tolerability of ME-344 Given in Combination with Topotecan (Hycamint?) in Patients with Solid Tumors</td>
<td>2</td>
<td>28/02/2017</td>
<td>Y</td>
</tr>
<tr>
<td>14/LO/1834</td>
<td>A Phase I randomised, placebo-controlled, double-blind, single and multiple ascending dose study of the tolerability and pharmacokinetics of GBT440 in healthy subjects and patients with Sickle Cell Disease</td>
<td>2</td>
<td>24/07/2015</td>
<td>Y</td>
</tr>
<tr>
<td>14/LO/1994</td>
<td>The AMARANTH study - A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled,Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer’s Disease</td>
<td>2</td>
<td>Open</td>
<td>N/A</td>
</tr>
<tr>
<td>14/LO/2143</td>
<td>Measurement of low-energy stimulation in patients with atrial fibrillation</td>
<td>15</td>
<td>15/12/2015</td>
<td>N/A</td>
</tr>
<tr>
<td>14/LO/2196</td>
<td>A phase 2, double-blind, parallel group, randomised, placebo controlled, proof of concept study to assess the safety and efficacy of OBE001 after oral administration in pregnant women with threatened preterm labour</td>
<td>7</td>
<td>Open</td>
<td>N/A</td>
</tr>
<tr>
<td>Study ID</td>
<td>Title</td>
<td>Status</td>
<td>Date</td>
<td>Sponsor Comment</td>
</tr>
<tr>
<td>---------</td>
<td>----------------------------------------------------------------------</td>
<td>-------------------------</td>
<td>------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>14/NE/1072</td>
<td>A PHASE II RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED BRONCHOSCOPY STUDY TO EVALUATE THE EFFECTS OF LEBRIKIZUMAB ON AIRWAY EOSINOPHILIC INFLAMMATION IN PATIENTS WITH UNCONTROLLED ASTHMA ON INHALED CORTICOSTEROIDS AND A SECOND CONTROLLER MEDICATION</td>
<td>Open</td>
<td>N/A</td>
<td>Inclusion/exclusion criteria for study is very narrow and no patients have been recruited to date despite actively screening. Sponsor is aware of difficulties and a meeting between site and sponsor is to take place to discuss restrictive inclusion criteria.</td>
</tr>
<tr>
<td>14/NW/0008</td>
<td>Golimumab: A Phase 4, UK Open Label, Single arm Study on its Utilization and Impact in Ulcerative Colitis</td>
<td>Closed - In Follow Up</td>
<td>31/03/2016</td>
<td>Study closed to recruitment by sponsor before agreed date to recruit by.</td>
</tr>
<tr>
<td>14/NW/0036</td>
<td>ESPAC 5 - Four arm, prospective, multicentre, randomised feasibility trial of immediate surgery compared with neoadjuvant chemotherapies and neoadjuvant chemoradiotherapy</td>
<td>Open</td>
<td>N/A</td>
<td>Date agreed to recruit to target not yet passed.</td>
</tr>
<tr>
<td>14/NW/0130</td>
<td>A randomised, double blind, multi-center, placebo-controlled study to evaluate the efficacy, safety, and tolerability of NT100 in pregnant women with a history of unexplained recurrent pregnancy loss (RPL)</td>
<td>20 01/06/2015</td>
<td>Open</td>
<td>Y Study delivered to time and target.</td>
</tr>
<tr>
<td>14/NW/0156</td>
<td>OlymiAPD - Olaparib monotherapy V Physicians choice chemotherapy</td>
<td>1 31/10/2015</td>
<td>Open</td>
<td>N/A Date agreed to recruit to target not yet passed.</td>
</tr>
<tr>
<td>14/NW/0290</td>
<td>Registry of Deep Brain Stimulation with the VERCISE? System: Vercise DBS Registry</td>
<td>10</td>
<td>Open</td>
<td>N/A No date agreed with sponsor.</td>
</tr>
<tr>
<td>14/NW/1354</td>
<td>Komilostim in Thrombocytopenic Paediatric Patients with ITP</td>
<td>5 28/02/2017</td>
<td>Open</td>
<td>N/A Date agreed to recruit to target not yet passed.</td>
</tr>
<tr>
<td>14/NW/1427</td>
<td>A Phase 3, Randomized Study Investigating the Safety of CVT-301 (Levodopa Inhalation Powder) in Parkinsons Disease Patients With Motor Response Fluctuations (OFF Phenomena) Compared to an Observational Cohort Control</td>
<td>4 13/12/2017</td>
<td>Open</td>
<td>N/A Date agreed to recruit to target not yet passed.</td>
</tr>
<tr>
<td>14/SC/0037</td>
<td>A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, EFFICACY AND SAFETY STUDY OF GANTENERUMAB IN SUBJECTS WITH MILD ALZHEIMER’S DISEASE</td>
<td>6 31/01/2016</td>
<td>Open</td>
<td>N/A Date agreed to recruit to target not yet passed.</td>
</tr>
<tr>
<td>14/SC/0038</td>
<td>PET IMAGING SUBSTUDY ASSOCIATED WITH: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, EFFICACY, AND SAFETY STUDY OF GANTENERUMAB IN PATIENTS WITH MILD ALZHEIMER’S DISEASE</td>
<td>5 31/01/2016</td>
<td>Open</td>
<td>N/A Date agreed to recruit to target not yet passed.</td>
</tr>
<tr>
<td>14/SC/0132</td>
<td>A phase I, open label study to assess the pharmacokinetic profile, safety and tolerability of OB6001 after a single oral administration in pregnant women with medically indicated pregnancy termination.</td>
<td>6 31/10/2014</td>
<td>Open</td>
<td>N Study recruits pregnant women who need to have a termination. It requires them to have surgical procedure but many of them do not consent as feel emotionally vulnerable and do not want to have surgery.</td>
</tr>
<tr>
<td>14/SC/0178</td>
<td>A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idealisilin in Combination with Bemdamustine and Rutiximab for Previously Untreated Chronic Lymphocytic Leukemia</td>
<td>2 31/08/2016</td>
<td>Closed - Follow Up Complete</td>
<td>Y Study delivered to time and target.</td>
</tr>
<tr>
<td>14/SC/0262</td>
<td>A Phase IV, prospective, open-label, uncontrolled, European Study in patients with neovascular Age-related macular degeneration (nAMD), evaluating the efficacy and safety of switching From intravitreal Alfilbercept to Ranibizumab 0.5mg: SAFARI study</td>
<td>6 30/10/2016</td>
<td>Open</td>
<td>N/A Date agreed to recruit to target not yet passed.</td>
</tr>
<tr>
<td>14/SC/1014</td>
<td>A Randomized, DoubleBlind, Phase 3 Study of the JAK1/2 Inhibitor, Ruxolitinib or Placebo in Combination With Capcabtine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas (The JANUS 1 study)</td>
<td>2 26/01/2016</td>
<td>Open</td>
<td>Y Study delivered to time and target.</td>
</tr>
<tr>
<td>14/SC/1014</td>
<td>A Randomized, DoubleBlind, Phase 3 Study of the JAK1/2 Inhibitor, Ruxolitinib or Placebo in Combination With Capcabtine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas (The JANUS 1 study)</td>
<td>2 26/01/2016</td>
<td>Open</td>
<td>Y Study delivered to time and target.</td>
</tr>
<tr>
<td>14/SW/0091</td>
<td>Randomized, Doubleblind, Multicenter, Phase 3 Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous NonSmall Cell Lung Cancer (NSCLC)</td>
<td>6 31/03/2016</td>
<td>Open</td>
<td>N/A Date agreed to recruit to target not yet passed.</td>
</tr>
<tr>
<td>14/WA/0170</td>
<td>A Phase 3, Randomized Study To Evaluate the Efficacy of Momelotinib versus Best Available Therapy in Anemic or Thrombocytopenic Subjects with Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis,</td>
<td>2 01/10/2020</td>
<td>Open</td>
<td>Y Study delivered to time and target.</td>
</tr>
<tr>
<td>Study Code</td>
<td>Study Title</td>
<td>Sponsorship</td>
<td>Status</td>
<td>Date</td>
</tr>
<tr>
<td>------------</td>
<td>------------------------------------------------------------------------------</td>
<td>-------------</td>
<td>--------------</td>
<td>------------</td>
</tr>
<tr>
<td>14/WM/1055</td>
<td>A prospective, multicenter, randomized, double-blind, placebo-controlled, 2 parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with FOLFIIRI to placebo in combination with FOLFIIRI</td>
<td></td>
<td>Open</td>
<td>01/09/2017</td>
</tr>
<tr>
<td>14/WM/1056</td>
<td>A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects with Chronic HCV</td>
<td></td>
<td>Closed - Follow Up Complete</td>
<td>N/A</td>
</tr>
<tr>
<td>14/WM/1202</td>
<td>B0401016: A Phase 1b, Randomized, Double-Blind (Sponsor Open), Placebo-Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of PF-04479436 In Subjects With Stable Sickle Cell Disease</td>
<td></td>
<td>Open</td>
<td>N/A</td>
</tr>
<tr>
<td>14/WM/1262</td>
<td>An Open Label Study of Sofosbuvir/GS5816 Fixed Dose Combination in Subjects with Chronic HCV Infection</td>
<td></td>
<td>Open</td>
<td>N/A</td>
</tr>
<tr>
<td>14/WS/1105</td>
<td>REVEAL 101MS408 Multicenter study of Natalizumab v Fingolimod in MS</td>
<td></td>
<td>Open</td>
<td>N/A</td>
</tr>
<tr>
<td>14/YH/0049</td>
<td>A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of the Combined Lysis of Thrombus with Ultrasound and Systemic Tissue Plasminogen Activator (Ipa) for Emergent Revascularization (CLOTBUST-ER) in Acute Ischemic Stroke.</td>
<td></td>
<td>Closed - Follow Up Complete</td>
<td>N</td>
</tr>
<tr>
<td>14/YH/0123</td>
<td>An Expanded Access Protocol for Idelalisib (GS-1101) in Combination with Rituximab for Relapsed, Previously Treated Subjects with Chronic Lymphocytic Leukemia.</td>
<td></td>
<td>Closed - Follow Up Complete</td>
<td>Y</td>
</tr>
<tr>
<td>14/YH/1057</td>
<td>A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks with Sofosbuvir and Ribavirin for 24 Weeks in Subjects with Chronic Genotype 3 HCV Infection</td>
<td></td>
<td>Closed - Follow Up Complete</td>
<td>N/A</td>
</tr>
<tr>
<td>14/YH/1153</td>
<td>An Open-Label, Extension Study of the Effects of Leuco-methylthioninium bi (Hydromethanesulfonate) in Subjects with Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia</td>
<td></td>
<td>Open</td>
<td>N/A</td>
</tr>
<tr>
<td>14/YH/1234</td>
<td>A phase III, doubleblind, randomised study to assess the efficacy and safety of AZD2249 versus a standard of care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as frontline treatment in patients with (...) NonSmall Cell Lung Cancer</td>
<td></td>
<td>Open</td>
<td>N/A</td>
</tr>
<tr>
<td>15/LO/0140</td>
<td>CLEANER Assessment of efficacy and safety for a new wound dressing URGO 310 3166 in the local treatment of venous or mixed leg ulcers: a European, randomised clinical trial.</td>
<td></td>
<td>Open</td>
<td>N/A</td>
</tr>
<tr>
<td>15/LO/0210</td>
<td>An exploratory, open-label, multicenter study to evaluate the safety and efficacy of ATIR, donor T-lymphocytes depleted ex vivo of host alloreactive T-cells, in patients with a hematologic malignancy, who received a CD34-selected (...) cell</td>
<td></td>
<td>Open</td>
<td>Y</td>
</tr>
<tr>
<td>15/WS/0037</td>
<td>A single-arm, post-market study of the Endo GI Reinforced Reload with Tri-Staple Technology</td>
<td></td>
<td>Open</td>
<td>N/A</td>
</tr>
</tbody>
</table>